Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. 2007 Mar;132(3):863-73; quiz 1165-6. Epub 2006 Dec 3

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Cancer Risk in Pediatric-Onset Inflammatory Bowel Disease: A Population-Based Danish Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B cell-Based Vaccine Development

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Crohn's Disease With Progressive Renal Impairment

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  4. Safety of Proton Pump Inhibitors Based on a Large, Multi-year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Remission of bile acid malabsorption symptoms following treatment with the glucagon-like peptide 1 receptor agonist liraglutide

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Jeffrey Hyams
  • Wallace Crandall
  • Subra Kugathasan
  • Anne Griffiths
  • Allan Olson
  • Jewel Johanns
  • Grace Liu
  • Suzanne Travers
  • Robert Heuschkel
  • James Markowitz
  • Stanley Cohen
  • Harland Winter
  • Gigi Veereman-Wauters
  • George Ferry
  • Robert Baldassano
  • NN NN
Vis graf over relationer
BACKGROUND AND AIMS: The REACH study evaluated the safety and efficacy of infliximab in children with moderately to severely active Crohn's disease. METHODS: Patients (n = 112) with a Pediatric Crohn's Disease Activity Index (PCDAI) score >30 received infliximab 5 mg/kg at weeks 0, 2, and 6. Patients responding to treatment at week 10 were randomized to infliximab 5 mg/kg every 8 or 12 weeks through week 46. A concurrent immunomodulator was required. Clinical response (decrease from baseline in the PCDAI score > or =15 points; total score < or =30) and clinical remission (PCDAI score < or =10 points) were evaluated at weeks 10, 30, and 54. RESULTS: At week 10, 99 of 112 (88.4%) patients responded to infliximab (95% confidence interval: [82.5%, 94.3%]) and 66 of 112 (58.9%) patients achieved clinical remission (95% confidence interval: [49.8%, 68.0%]). At week 54, 33 of 52 (63.5%) and 29 of 52 (55.8%) patients receiving infliximab every 8 weeks did not require dose adjustment and were in clinical response and clinical remission, respectively, compared with 17 of 51 (33.3%) and 12 of 51 (23.5%) patients receiving treatment every 12 weeks (P = .002 and P < .001, respectively). CONCLUSIONS: Pediatric patients responding to an induction regimen of infliximab were more likely to be in clinical response and remission at week 54 without dose adjustment when their maintenance therapy was given every 8 weeks rather than every 12 weeks. Allowing for dose intensification in the case of relapse, remission rates, but not response rates, at week 54 were superior with every 8-week dosing compared with every 12-week dosing.
Udgivelsesdato: 2007-Mar
OriginalsprogEngelsk
TidsskriftGastroenterology
Vol/bind132
Udgave nummer3
Sider (fra-til)863-73; quiz 1165-6
ISSN0016-5085
DOI
StatusUdgivet - 2006

ID: 32489534